CytomX Therapeutics, Inc. (NASDAQ:CTMX)
| Market Cap | $442.55M-47.7% |
| Revenue (ttm) | $14.03M-87.7% |
| Net Income | -$85.42M-404.9% |
| EPS | -$0.45-207.8% |
| Shares Out | 218.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,867,850 |
| Open | $2.02 |
| Previous Close | $2.05 |
| Day's Range | $1.99 - $2.16 |
| 52-Week Range | $1.87 - $8.21 |
| Beta | 2.24 |
| Analysts | Buy |
| Price Target | $10.71(+427.59%) |
| Earnings Date | Feb 24, 2027 |
About CTMX
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating CTMX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 24, 2027Earnings report
$CTMX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CTMX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CTMX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CTMX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CTMX Revenue by Segment
| Internal costs | $9.45M | 63.39% |
| Varseta-M (EpCAM) | $3.79M | 25.41% |
| CX-801 (IFNAlpha2b) | $949.00K | 6.36% |
| Other income | $294.00K | 1.97% |
| Other Wholly Owned and Partnered Programs | $239.00K | 1.60% |
| CX-904 (EGFRxCD3) | $188.00K | 1.26% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CTMX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CTMX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CTMX
| VTIVanguard Morningstar Total Stock Market ETF | $11.49M |
| XBIState Street SPDR S&P Biotech ETF | $10.67M |
| IWMiShares Russell 2000 ETF | $10.04M |
| VXFVanguard Extended Market ETF | $5.44M |
| IBBiShares Biotechnology ETF | $3.04M |
| VTWOVanguard Russell 2000 ETF | $2.60M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CTMX’s recent data — informational, not investment advice
What’s Behind the Score
News check: CytomX achieved milestone payments from strategic Regeneron collaboration, demonstrating validation of core technology platform.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.52% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.36% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 0.32% |
| CANC | Tema Oncology ETF | 0.25% |
| XBI | State Street SPDR S&P Biotech ETF | 0.10% |
| IWC | iShares Micro-Cap ETF | 0.10% |
| FFSM | Fidelity Fundamental Small-Mid Cap ETF | 0.06% |
| FSMO | Fidelity Fundamental Small-Mid Cap ETF | 0.06% |
| STSB | iShares Factors US Small Blend Style ETF | 0.06% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.03% |
| IBB | iShares Biotechnology ETF | 0.03% |
| PWS | Pacer WealthShield ETF | 0.02% |
Weight is the stock’s share of each fund’s holdings.
